Achieve Life Sciences (NASDAQ: ACHV) has announced the promotion of Mark Rubenstein, MD, from interim chief medical officer (CMO) to CMO.
Dr. Rubinstein brings more than two decades of experience in clinical medicine, scientific research, and medical affairs leadership, with a strong focus on nicotine cessation and preventive medicine. Recently, he co-authored a paper in the peer-reviewed medical journal Thorax demonstrating cytisinicline’s potential efficacy and tolerability for smoking cessation in individuals with COPD.
“Dr. Rubinstein has been an excellent addition to our leadership team during this pivotal period,” said Rick Stewart, president and CEO of Achieve. “His reputation and expertise in nicotine cessation strengthens our medical leadership as we advance toward regulatory review. We are pleased to confirm his appointment to the permanent CMO role, and we’re confident the team will continue to drive our progress forward.”
